Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association

Sunesis Pharmaceuticals, Inc.

today announced that two poster presentations describing results from the VALOR trial will be presented at the 20th Congress of the European Hematology Association (EHA) being held June 11 – 14, 2015, at the Reed Messe Wien Exhibition & Congress Center in Vienna, Austria. VALOR is a randomized, double-blind, placebo-controlled Phase 3 trial which enrolled 711 adult patients with first relapsed or refractory AML at 124 leading sites in 15 countries. Patients were stratified for age, geographic region and disease status and randomized one to one to receive either vosaroxin and cytarabine or placebo and cytarabine. The details for the poster presentations are as follows: Date & Time: Friday, June 12, 2015, from 5:15 p.m. to 6:45 p.m. European Central Time Poster Title: Improved survival in patients ≥60 with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: results from the Phase 3 VALOR study Abstract Number: 4192 Session Title: Acute myeloid leukemia – Clinical 2 Location: Poster area (Hall C) The full abstract can be viewed here here. Date & Time: Friday, June 12, 2015, from 5:15 p.m. to 6:45 p.m. European Central Time Poster Title: Allogeneic transplant in patients ≥60 years of age with first relapsed or refractory acute myeloid leukemia after treatment with vosaroxin or placebo plus cytarabine: results from VALOR Abstract Number: 4693 Session ID: Acute myeloid leukemia – Clinical 1 Location: Poster area (Hall C) The full abstract can be viewed here here. The company will also publish data from VALOR that will be on display as an E-poster: Date & Time: From Friday, June 12, 2015 at 9:30 a.m. to Saturday, June 13, 2015 at 6:45 p.m. European Central Time Poster Title: Impact of cytogenetics on clinical outcome in patients with first relapsed or refractory acute myeloid leukemia treated with vosaroxin plus cytarabine: results from VALOR Abstract Number: 4730 Location: E-Poster Screens The full abstract can be viewed here here. Conference Call Information Sunesis will host a conference call to discuss the data on Friday, June 12th at 10:00 a.m. Eastern Time. The call can be accessed by dialing (866) 515-2908 (U.S. and Canada) or (617) 399-5122 (international), and entering passcode 93595855. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks. About QINPREZO™ (vosaroxin) QINPREZO™ (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Preclinical data demonstrate that vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Both the U.S. Food and Drug Administration (FDA) and European Commission have granted orphan drug designation to vosaroxin for the treatment of AML. Additionally, vosaroxin has been granted fast track designation by the FDA for the potential treatment of relapsed or refractory AML in combination with cytarabine. Vosaroxin is an investigational drug that has not been approved for use in any jurisdiction. The trademark name QINPREZO is conditionally accepted by the FDA and the EMA as the proprietary name for the vosaroxin drug product candidate.